Meta‐analysis: Prevalence of significant or advanced fibrosis in adults with alpha‐1‐antitrypsin deficiency

Abstract

SummaryBackgroundThe prevalence of liver fibrosis detected by non‐invasive imaging in alpha‐1‐antitrypsin (AAT) deficiency has not been systematically assessed.AimsWe conducted a systematic review and meta‐analysis to determine the prevalence of significant fibrosis and advanced fibrosis in AAT deficiency based on non‐invasive imaging.MethodsMedline and Embase electronic databases were searched for studies from inception to 13 November 2022 that provided data for the prevalence of fibrosis in adults with AAT deficiency. A generalised linear mixed model with Clopper–Pearson intervals was used to pool single‐arm outcomes.ResultsOf the 214 records identified, 8 studies were included. Five studies assessed fibrosis using vibration‐controlled transient elastography. The prevalence of significant fibrosis (defined as ≥7.1 kPA) in Z homozygosity, Z heterozygosity and non‐carrier status was 22.10% (five studies, 95% CI: 17.07–28.12), 9.24% (three studies, 95% CI: 4.68–17.45) and 5.38% (one study, 95% CI: 3.27–8.73), respectively, p < 0.0001, and the prevalence of advanced fibrosis (defined as ≥9.5 kPa) was 8.13% (five studies, 95% CI: 4.60–13.96), 2.96% (three studies, 95% CI: 1.49–5.81) and 1.08% (one study, 95% CI: 0.35–3.28), respectively, p = 0.003. There were limited data regarding the use of magnetic resonance elastography or acoustic radiation force impulse to assess for fibrosis.ConclusionMore than one in five adult individuals with AAT deficiency and Z homozygosity harbour significant fibrosis, and nearly 1 in 10 harbours advanced fibrosis. The risk of fibrosis increases incrementally with the frequency of Pi*Z mutations.